5
Dec
2022
Tag: pharma
21
Nov
2022
Bionest
Competitors Collaborate to Understand Shared DMD Adverse Event
Adverse responses to experimental gene therapies for Duchenne muscular dystrophy leads to unique collaboration between pharma competitors.
7
Nov
2022
Bionest
Down to the Wire: The Race Between Amgen and Mirati for KRAS-Inhibitor Approvals
Who is ahead in the race for KRAS-inhibitor approval? We explore the latest drug development updates for sotorasib and adagrasib.
24
Oct
2022
Bionest
A New Advance in the Treatment of Major Depressive Disorder
Could the FDA approval of Auvelity usher in a new class of antidepressants? The new oral treatment for depression works with the glutamate receptor NMDA.
10
Oct
2022
Bionest
Are the Blues Ending for Bluebird?
Gene therapy developer bluebird bio may be turning a corner, with recent FDA approvals for two of its rare disease therapeutics.
19
Sep
2022
Bionest
ASCO 2022 – Part 1: Redefining Breast Cancer Classification and Treatment
An important new development in breast cancer greatly expands the number of patients who might benefit from HER2-targeting treatment, as shared at ASCO 2022
6
Sep
2022
Bionest
Potential Game Changers in Diabetes and Obesity
Is metformin on the way out as a first-line therapy for type 2 diabetes, to be replaced by tirzepatide? We examine new treatments for diabetes and obesity.
25
Jul
2022
Bionest
Big Tech’s Foray in Healthcare
By bringing its unique strengths to specific health problems, can Big Tech play a larger role in many facets of healthcare?
25
Apr
2022
Bionest
Biosimilars on the Rise, Spurring Company Integration and Consolidation
From one to 34: Biosimilars are on the rise. How will it affect the pharmaceutical market for companies and consumers?
28
Mar
2022